We Present the Scientific Evidence for EECP Transparently
This page is not promotional material. It aims to present the published peer-reviewed medical literature on EECP (Enhanced External Counterpulsation) without concealing the type of evidence or its limitations. For each study below, the type (randomized controlled trial, systematic review/meta-analysis, or observational registry data), author, journal, year, and a link to the original source are provided. You can also find a shorter summary of this topic in our EECP Scientific Research article.
Studies Examining EECP With a Sham-Controlled Design
MUST-EECP (Multicenter Study of Enhanced External Counterpulsation)
A multicenter study in which 139 patients with chronic angina were randomized to active EECP (n=72) or a sham/placebo device (n=67). The active treatment group showed a significant reduction in angina episode frequency and exercise-induced ischemia duration compared with the sham group. Although the improvement in quality-of-life measures was larger, only 3 of 9 parameters reached statistical significance. A subsequent Cochrane review highlighted this study's methodological limitations (low response rate, exclusion of the most severe CCS Class IV patients).
View on JACC (DOI)PEECH (Prospective Evaluation of EECP in Congestive Heart Failure)
A randomized study evaluating the effect of EECP on exercise tolerance in 187 heart failure patients with a left ventricular ejection fraction ≤35%. The proportion of patients achieving a ≥60-second increase in exercise duration was higher in the EECP group than in the control group (35% vs. 25%), with improvement observed in the Minnesota Living With Heart Failure score. No significant difference was found between groups in peak VO2 (a measure of exercise capacity) across the full patient group, suggesting that EECP's effect can vary depending on the parameter measured.
View on JACC (DOI)Analyses That Combine Multiple Studies
Does EECP Reduce Symptoms of Chronic and Refractory Angina?
After screening 318 sources, only 1 eligible randomized trial (MUST-EECP) could be identified. The Cochrane authors stated that the available evidence is insufficient to draw a firm conclusion about the efficacy and safety of EECP, citing limitations in study quality and the inability to generalize the results to the most severely symptomatic patient group. This is the most notable cautionary assessment in the EECP literature, and it is not hidden on this page.
View on Cochrane LibraryEECP Efficacy by CCS Class in Refractory Angina
An updated meta-analysis pooling the change in Canadian Cardiovascular Society (CCS) angina class after EECP in patients with chronic refractory angina. The included studies reported an average improvement in CCS class; however, the authors note that most of the analyzed studies were uncontrolled/single-arm in design, which limits the strength of the evidence.
View on PubMedThe Effect of EECP on Endothelial Function
This meta-analysis, which pools randomized controlled trials, shows that EECP may be associated with improvement in markers of endothelial function such as flow-mediated dilation (FMD). This is indirect (surrogate) evidence for EECP's proposed microcirculatory/vascular wall mechanism; it is not a direct clinical outcome measure (death, MI, hospitalization), and this distinction matters.
View on PubMedDoes EECP Meaningfully Affect Myocardial Perfusion?
A systematic review pooling imaging studies (SPECT/perfusion tests); while improvement in myocardial perfusion is reported in some patients after EECP, the review highlights significant heterogeneity between studies in terms of methodology and patient selection.
View on PLOS ONEReal-World Patient Records
Registry studies provide real-world data from thousands of patients, but because they lack a control group, they do not prove causation; results may also be influenced by factors other than the treatment itself (natural course over time, concurrent treatments, etc.).
International EECP Patient Registry (IEPR) — Long-Term Follow-Up in Refractory Angina
Long-term follow-up data from a multicenter registry of patients who received EECP for chronic refractory angina. The registry reports improvement in angina class and a reduction in angina episode frequency in a significant proportion of patients after treatment. This is not a randomized trial; there is no control group, and the results should be interpreted accordingly.
View on PubMedHow Is EECP Positioned in Guidelines and by Regulatory Authorities?
ACC/AHA Stable Ischemic Heart Disease Guideline
In the joint guideline update from the American College of Cardiology and the American Heart Association, EECP is listed as an option that may be considered (Class IIb, Level of Evidence B) in patients with stable ischemic heart disease whose refractory angina persists despite optimal medical therapy. In guideline terminology, Class IIb means the benefit is less well supported by evidence/opinion; it does not mean a first-line or strongly recommended treatment.
View Guideline Summary on ACC.orgUS FDA Device Classification
The US Food and Drug Administration (FDA) has classified external counterpulsation (ECP) devices used for the refractory angina indication as Class II medical devices, subject to the 510(k) clearance process. This page and other pages on this site deliberately avoid the term "FDA-approved," because that term technically applies to Class III devices that go through the PMA (Premarket Approval) process. The correct term for EECP devices is FDA-cleared Class II device.
View Regulatory SourceAn Honest Assessment of the Evidence
Common Questions About Clinical Evidence
Is there scientific evidence for EECP?
Yes; there is a randomized controlled trial (MUST-EECP), observational registry data (IEPR), and several meta-analyses. However, the Cochrane systematic review states that this evidence base is not yet sufficient to conclusively prove efficacy. It's not that there is no evidence — it's a limited and still-developing evidence base.
What exactly did the MUST-EECP study show?
In this randomized study of 139 patients, the group receiving active EECP showed a significant reduction in angina episode frequency compared with the sham group. However, the study's sample size was small, and the most severely symptomatic patients were not included.
Is EECP an FDA-approved treatment?
No, that is not the accurate term. EECP devices have been classified by the FDA as Class II medical devices and cleared for marketing through the 510(k) process. This is not the same regulatory category as treatments that go through the PMA (Premarket Approval) process, which is why we do not use the term "FDA-approved" on our site.
How strong is the level of evidence, and what should I consider when deciding on treatment?
The current evidence consists of a limited number of randomized trials, a few meta-analyses, and large-scale but uncontrolled registry data. Whether EECP is right for you should be decided by a cardiology team, based on an evaluation of your current test results and overall health.
Let's Assess Your Situation After Reviewing the Evidence
You can find out whether EECP is a meaningful option for your clinical situation by getting a free initial assessment from our cardiology team.